Prescribing InformationFor Patients
(telotristat ethyl)
Combination for Control
Inhibit serotonin overproduction inside the tumor cell to control Carcinoid Syndrome Diarrhea.1
SSA=somatostatin analog.
Xermelo is the only oral therapy that controls serotonin overproduction at its source—inside the tumor cell.1,2
SSAs alone may not be enough
Why Combination Therapy
Control serotonin overproduction at its source1
Watch our MOA Video
What your patients need to know
Using Xermelo


1. XERMELO prescribing information. The Woodlands, TX: Lexicon Pharmaceuticals, Inc.; February 2017.2. Molina-Cerrillo J, Alonso-Gordoa T, Martínez-Sáez O, Grande E. Oncologist. 2016;21:701-707.

You may report an adverse event related to TerSera Therapeutics products by calling 1-844-334-4035 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. The FDA has established a reporting service known as MedWatch where healthcare professionals and consumers can report serious problems they suspect may be associated with the drugs and medical devices they prescribe, dispense, or use. Visit MedWatch or call 1-800-FDA-1088.

Xermelo® is a registered trademark of TerSera Therapeutics LLC or its affiliates.
© 2020 TerSera Therapeutics LLC. All rights reserved.
XER-P-0040 V4 (10/2022)


  • Contraindications: XERMELO is contraindicated in patients with a history of a hypersensitivity reaction to telotristat. Reactions have included angioedema, rash and pruritis.
  • Warnings and Precautions: XERMELO may cause constipation, which can be serious. Serious complications of constipation have been reported during clinical trials and post marketing with individual reports of intestinal perforation, obstruction, and fecaloma. Monitor for signs and symptoms of constipation and/or severe, persistent, or worsening abdominal pain in patients taking XERMELO. Discontinue XERMELO if severe constipation or severe, persistent, or worsening abdominal pain develops.
  • Adverse Reactions: In a clinical trial of patients with carcinoid syndrome diarrhea and 4-12 bowel movements per day, the most common adverse reactions (≥5%) include nausea, headache, increased gamma-glutamyl transferase, depression, flatulence, decreased appetite, peripheral edema, and pyrexia. In a second clinical trial of patients with carcinoid syndrome diarrhea and less than 4 bowel movements per day, additional adverse reactions of abdominal pain and constipation were reported in ≥5% of patients.
  • Drug Interactions: If necessary, consider increasing the dose of concomitant CYP3A4 and CYP2B6 substrates, as XERMELO may decrease their systemic exposure. If combination treatment with XERMELO and short-acting octreotide is needed, administer short-acting octreotide at least 30 minutes after administering XERMELO.
  • Use in Special Populations: XERMELO is not recommended in patients with moderate and severe hepatic impairment.


XERMELO is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

To report suspected adverse reactions, contact the FDA at 1-800-FDA-1088 or You may also contact TerSera Therapeutics at 1-844-334-4035 or

Please see Full Prescribing Information.